Covista Inc. (CVSA) AI Stock Analysis

Covista Inc., formerly known as Adtalem Global Education Inc., provides healthcare education across the United States, Barbados, St. Kitts, and St. Maarten. The company operates through three segments: Chamberlain, Walden, and Medical and Veterinary. Its educational institutions include Chamberlain University, Walden University, American University of the Caribbean School of Medicine, Ross University School of Medicine, and Ross University School of Veterinary Medicine. Covista awards bachelor's, master's, and doctoral degrees alongside certificate programs in nursing, veterinary medicine, health professions, counseling, business, psychology, and public health. Headquartered in Chicago, Illinois, the company employs 4,736 people.

Covista grew revenue from $1.38B in FY2022 to $1.95B in FY2026, achieving a 5-year revenue CAGR of 16.6%. During this period, net income reversed from -$162.5M in FY2022 to $251.6M in FY2026, with diluted EPS expanding from $3.55 to $8.25. Profitability showed sustained gains as gross margin widened from 47.2% to 57.3%, while operating margin improved from 11.3% to 19.6%. For the latest quarter ended June 30, 2026, revenue increased 9.7% year-over-year, and earnings rose 43.2% year-over-year.

As of June 30, 2026, Covista held $406.3M in cash and short-term investments against total debt of $905.5M, leaving net debt at $499.2M. The company maintains a current ratio of 1.09 and a debt-to-equity ratio of 0.63 against $1.45B in shareholders' equity. Operating cash flow totaled $470.4M in FY2026, funding capital expenditures of $77.7M and yielding $392.7M in free cash flow. Covista directed $239.9M toward share buybacks in FY2026, contributing to a 30.8% share count reduction over 5 years.

At a closing price of $126.75 on October 16, 2026, Covista carried a market capitalization of $4.29B and an enterprise value of $4.69B. The stock trades at a trailing P/E of 16.9x and a forward P/E of 13.6x, below the median of its US-listed Consumer Defensive peers at 18.6x and 14.3x, respectively. Its EV/EBITDA multiple of 10.3x also sits below the peer median of 11.7x, while its price-to-sales ratio of 2.2x is higher than the peer median of 0.7x. Over the past year, Covista fell 14.1% compared to a 16.8% return for SPY, though its 5-year return of 248.1% outperformed SPY's 83.0%.

Covista holds 2 Strong Buy, 1 Buy, and 1 Hold rating among analysts, with no Sell ratings. The mean price target of $158.75 represents a 25.2% premium over the last close of $126.75. Covista beat EPS estimates in each of the last 4 quarters. For the current fiscal year ending June 30, 2027, consensus estimates project revenue of $2.07B and EPS of $9.04, representing 9.6% earnings growth. The next earnings release is scheduled for October 29, 2026.

This page is an AI-written research summary of Covista Inc. (CVSA). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: CVSA income statement, CVSA balance sheet, CVSA key metrics, CVSA analyst forecast, CVSA chart. See the CVSA stock overview for the latest quote and news.